BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 28013117)

  • 1. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.
    Yang JD; Larson JJ; Watt KD; Allen AM; Wiesner RH; Gores GJ; Roberts LR; Heimbach JA; Leise MD
    Clin Gastroenterol Hepatol; 2017 May; 15(5):767-775.e3. PubMed ID: 28013117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.
    Young K; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
    J Viral Hepat; 2017 Sep; 24(9):789-796. PubMed ID: 28273387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
    Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of obesity and diabetes on waitlist survival, probability of liver transplantation and post-transplant survival among chronic hepatitis C virus patients.
    Aguilar M; Liu B; Holt EW; Bhuket T; Wong RJ
    Liver Int; 2016 Aug; 36(8):1167-75. PubMed ID: 26858016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit.
    Su F; Yu L; Berry K; Liou IW; Landis CS; Rayhill SC; Reyes JD; Ioannou GN
    Gastroenterology; 2016 Feb; 150(2):441-53.e6; quiz e16. PubMed ID: 26522262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC.
    Shingina A; DeWitt PE; Dodge JL; Biggins SW; Gralla J; Sprague D; Bambha K
    Transplantation; 2019 Jan; 103(1):140-148. PubMed ID: 30451739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.
    Younossi ZM; Stepanova M; Ong J; Trimble G; AlQahtani S; Younossi I; Ahmed A; Racila A; Henry L
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):580-589.e5. PubMed ID: 32531342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
    Wong RJ; Aguilar M; Cheung R; Perumpail RB; Harrison SA; Younossi ZM; Ahmed A
    Gastroenterology; 2015 Mar; 148(3):547-55. PubMed ID: 25461851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ; Kim WR; Flemming JA
    Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.
    Noureddin M; Vipani A; Bresee C; Todo T; Kim IK; Alkhouri N; Setiawan VW; Tran T; Ayoub WS; Lu SC; Klein AS; Sundaram V; Nissen NN
    Am J Gastroenterol; 2018 Nov; 113(11):1649-1659. PubMed ID: 29880964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
    Lewin SM; Mehta N; Kelley RK; Roberts JP; Yao FY; Brandman D
    Liver Transpl; 2017 Aug; 23(8):1015-1022. PubMed ID: 28340509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965.
    Shirazi F; Wang J; Wong RJ
    J Clin Exp Hepatol; 2020; 10(1):30-36. PubMed ID: 32025164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.
    Kim WR; Terrault NA; Pedersen RA; Therneau TM; Edwards E; Hindman AA; Brosgart CL
    Gastroenterology; 2009 Nov; 137(5):1680-6. PubMed ID: 19632234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    Younossi ZM; Stepanova M; Saab S; Ahmed A; Lam B; Srishord M; Venkatesan C; Wai H; Henry L
    J Viral Hepat; 2016 Jan; 23(1):53-61. PubMed ID: 26289820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.